Side-by-side · Research reference
MGFvsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/55 cited
BHuman-MechanisticAUTO-DRAFTED12/39 cited
MGF
IGF-1Ec Splice Variant · Muscle-Specific
SQ · Research context only
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
MGF
Semax
Primary target
Satellite cells (Pax7+) in skeletal muscleMoore 2018
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Satellite cell proliferation, myoblast differentiation, muscle fiber repair
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
—
—
Origin
Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016Vassilakos 2017
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
MGF
Semax
Synthetic peptide
24-amino-acid E-domain sequence
Corresponds to human IGF-1Ec exons 4-6 region.
—
Rodent cardiac model
200 μg/kg via peptide-eluting microstructures
Post-MI injection; improved ejection fraction by 8 weeks.
—
Acute delivery (mouse MI)
Single bolus within 12 hrs post-infarctionShioura 2014
Delayed decompensation; no human protocol established.
—
Human evidence
None — no published clinical trials
All dosing extrapolated from animal models.
—
Detection in doping
Full-length MGF detected via LC-MS in illicit productsThevis 2014
WADA-prohibited since 2005; no therapeutic indication.
—
Frequency
—
2–3× per day during cognitive demand
Lower / starter dose
—
100 mcg / dose
Duration
—
10–14 day cycles, repeated PRN
Reconstitution
—
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
—
Morning + early afternoon
Half-life
—
Short plasma; CNS effect lasts ~3–6 hr
04Side Effects & Safety
Parameter
MGF
Semax
Human safety data
None — no clinical trials published
—
Theoretical IGF-1 axis risk
Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)
—
Tumor promotion
IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer
—
Antibody development
Unknown — no longitudinal human exposure data
—
Local injection reaction
Presumed similar to other peptides (erythema, induration) — no direct evidence
—
Dysregulated expression with age
Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018
—
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Headache
—
Uncommon, transient
Long-term safety
—
Limited Western RCT data
Pregnancy / OB
—
Avoid
Absolute Contraindications
MGF
- ·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
- ·No established therapeutic use — investigational only
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
MGF
- ·Family history of IGF-1-axis malignancies
- ·Use outside research setting
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
MGF
Semax
1. No validated protocol
MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Synthetic peptide form
Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Animal delivery models
Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015Shioura 2014
Morning + early afternoon. Avoid evening (sleep disruption).
4. WADA prohibition
MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014
Refrigerate after reconstitution; light-protected.
5. Research context only
Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
MGF
+ BPC-157
Multi-pathwayMGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.
- MGF
- No established dose
- BPC-157
- 250–500 mcg SQ near injury site
- Context
- Animal models only
- Primary benefit
- Theoretical multi-tissue repair (muscle + tendon/ligament)
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.
- MGF
- No established dose
- TB-500
- 2–5 mg SQ weekly
- Context
- Animal models only
- Primary benefit
- Satellite cell activation + enhanced migration/angiogenesis
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation